Xvivo Perfusion AB (LTS:0RKL) Cyclically Adjusted Book per Share: kr43.82 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKL Xvivo Perfusion AB LTS:0RKL
84 GF Score
Price kr235.11
GF Value kr402.16
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Cyclically Adjusted Book per Share?

Xvivo Perfusion AB LTS:0RKL -9.09% 84 Cyclically Adjusted Book per Share is kr43.82 as of Jun. 2026. GuruFocus rates LTS:0RKL with a GF Score™ of 84/100 and a GF Value™ of kr402.16 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Xvivo Perfusion AB's adjusted book value per share for the three months ended in Jun. 2026 was kr69.850. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr43.82 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Xvivo Perfusion AB's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 20.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Xvivo Perfusion AB was 20.20% per year. The lowest was 20.20% per year. And the median was 20.20% per year.

As of today (2026-07-16), Xvivo Perfusion AB's current stock price is kr235.112. Xvivo Perfusion AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was kr43.82. Xvivo Perfusion AB's Cyclically Adjusted PB Ratio of today is 5.37.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Xvivo Perfusion AB was 16.47. The lowest was 4.11. And the median was 9.33.


Xvivo Perfusion AB  (LTS:0RKL) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Xvivo Perfusion AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=235.112/43.82
=5.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Xvivo Perfusion AB was 16.47. The lowest was 4.11. And the median was 9.33.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Xvivo Perfusion AB Cyclically Adjusted Book per Share Related Terms


Xvivo Perfusion AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Cyclically Adjusted Book per Share Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 24.09 29.79 35.62 40.85

Xvivo Perfusion AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.56 40.39 40.85 42.72 43.82

LTS:0RKL vs ABT, SYK, MDT: Cyclically Adjusted Book per Share Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Cyclically Adjusted PB Ratio falls into.


LTS:0RKL
84GF Score
Xvivo Perfusion AB LTS:0RKL
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xvivo Perfusion AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=69.85/134.1100*134.1100
=69.850

Current CPI (Jun. 2026) = 134.1100.

Xvivo Perfusion AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 13.314 101.138 17.655
201612 13.402 102.022 17.617
201703 13.368 102.022 17.573
201706 19.135 102.752 24.975
201709 19.042 103.279 24.726
201712 19.257 103.793 24.882
201803 19.405 103.962 25.032
201806 20.276 104.875 25.928
201809 20.250 105.679 25.698
201812 20.471 105.912 25.921
201903 20.551 105.886 26.029
201906 21.562 106.742 27.090
201909 21.903 107.214 27.398
201912 21.711 107.766 27.018
202003 22.153 106.563 27.880
202006 21.416 107.498 26.718
202009 36.279 107.635 45.203
202012 35.115 108.296 43.485
202103 35.583 108.360 44.039
202106 35.146 108.928 43.271
202109 35.216 110.338 42.803
202112 43.576 112.486 51.953
202203 44.055 114.825 51.454
202206 45.527 118.384 51.575
202209 46.737 122.296 51.252
202212 47.940 126.365 50.878
202303 48.501 127.042 51.199
202306 50.281 129.407 52.109
202309 61.212 130.224 63.039
202312 61.749 131.912 62.778
202403 63.594 132.205 64.510
202406 64.281 132.716 64.956
202409 66.135 132.304 67.038
202412 68.471 132.987 69.049
202503 66.428 132.825 67.071
202506 66.414 133.699 66.618
202509 66.470 133.480 66.784
202512 67.096 133.390 67.458
202603 68.871 133.560 69.155
202606 69.850 134.110 69.850

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr43.82 mean?
Xvivo Perfusion AB (LTS:0RKL) has a Cyclically Adjusted Book per Share of kr43.82 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Cyclically Adjusted Book per Share too high?
Xvivo Perfusion AB's current Cyclically Adjusted Book per Share is kr43.82. Overall, Xvivo Perfusion AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Cyclically Adjusted Book per Share compare to ABT and SYK?
Xvivo Perfusion AB's Cyclically Adjusted Book per Share of kr43.82 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Book per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Cyclically Adjusted Book per Share is kr43.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (LTS:0RKL) is currently considered Significantly Undervalued. The stock's GF Value™ is kr402.16, compared to a current price of kr235.11 — trading 41.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is kr43.82. Xvivo Perfusion AB's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Xvivo Perfusion AB (LTS:0RKL), the current Cyclically Adjusted Book per Share is kr43.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (LTS:0RKL) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of kr235.11 is trading 41.5% below its estimated GF Value™ of kr402.16. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for LTS:0RKL:

  • Cyclically Adjusted Book per Share: kr43.82
  • GF Value™: kr402.16 vs. price of kr235.11 (41.5% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RKL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
84GF Score

Get the complete analysis for LTS:0RKL

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr235.11
Price
kr402.16
GF Value